[go: up one dir, main page]

WO2014116013A1 - Composition pour le traitement, la prévention ou le soulagement de la dégénérescence maculaire, contenant un composé phénolique séparé de vaccinium uliginosum extrait en tant que substance active - Google Patents

Composition pour le traitement, la prévention ou le soulagement de la dégénérescence maculaire, contenant un composé phénolique séparé de vaccinium uliginosum extrait en tant que substance active Download PDF

Info

Publication number
WO2014116013A1
WO2014116013A1 PCT/KR2014/000606 KR2014000606W WO2014116013A1 WO 2014116013 A1 WO2014116013 A1 WO 2014116013A1 KR 2014000606 W KR2014000606 W KR 2014000606W WO 2014116013 A1 WO2014116013 A1 WO 2014116013A1
Authority
WO
WIPO (PCT)
Prior art keywords
macular degeneration
phenolic compound
quercetin
preventing
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2014/000606
Other languages
English (en)
Korean (ko)
Inventor
정수영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014116013A1 publication Critical patent/WO2014116013A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to a composition for treating, preventing or ameliorating macular degeneration containing a compound isolated from natural products.
  • macular degeneration the nerve tissue located in the central part of the inner retina of the eye. Most of the cells are gathered here, and the place where the image of the object is also the center of the macular and plays a very important role in vision. Ocular disease that causes degeneration of the macula due to various causes and causes vision disorders is called macular degeneration (macular degeneration), and macular degeneration is known as one of the three major blindness diseases along with glaucoma and diabetic retinal disease.
  • This macular degeneration affects central vision, causing blurred vision in the center of vision, making it difficult to perform sophisticated activities such as reading and driving due to central dark spots, schizophrenia (a symptom of being distorted) or loss of vision in the local area. It is a very serious disease that, in severe cases, can lead to blindness.
  • Age-related Macular Degeneration is the most common cause of vision loss in people 55 and older in developed countries. It is estimated that 10 million people in the United States suffer from various forms of macular degeneration. Life expectancy and current demographic growth are expected to triple this by 2020. However, not all age-related macular degenerations cause sudden, severe vision loss.
  • senile macular degeneration There are two types of senile macular degeneration, dry and wet senile macular degeneration. Wet senile macular degeneration results in a sudden loss of vision due to causing choroidal neovascularization in the central retina. However, only about 10% of senile macular degeneration is wet senile macular degeneration. Dry senile macular degeneration characterized by the presence of drusen (yellow precipitate between the retina and choroid) does not cause any leakage of blood or plasma. Dryness therefore does not result in a sudden loss of vision.
  • senile macular degeneration is characterized by a loss of central vision following death of photoreceptor cells and is thought to have a multifactorial etiology.
  • various factors eg smoking, obesity, eating habits, increased cholesterol in the blood, irradiation with blue light, etc.
  • degeneration of retinal pigment epithelium.
  • fat brown pigment lipofuscin
  • the accumulation of fat brown pigment (lipofuscin) in the center of the eye retina is known to be the largest in the retinal pigment epithelial cells below the center of the retina. This reflects the fact that there are many dense rod photoreceptors.
  • N-retinyl-N-retinylidene ethanolamine (produced as a by-product of all-trans-retinal in the outer disk) is the main chromophore of lipofucin and causes the formation of reactive oxygen species when exposed to blue light .
  • Blue light belongs to light having a relatively high amount of energy. When exposed to blue light of about 440 nm, photooxidation is induced to damage cells. Since A2E is sensitive to these blue light, it is thought that senile macular degeneration is related to lipofucin in retinal pigment epithelial cells. That is, continuous light exposure further promotes the death of retinal pigment epithelial cells of senile macular degeneration, which is one of the main causes of degeneration of photoreceptor cells.
  • Lutein is a representative example of a health functional food for preventing macular degeneration. Lutein protects the macula of the retina and maintains macular pigment density to prevent macular degeneration, but studies show that prolonged use of supplements containing carotenoids, such as lutein, increases the risk of developing lung cancer, especially for smokers Appeared. Therefore, it can be dangerous for smokers to take lutein-related products.
  • the present invention is to provide a composition for the treatment, prevention or improvement of macular degeneration comprising a phenolic compound isolated from the blueberry extract.
  • Polyphenols and anthocyanins are the most abundant components of blueberry extracts and the most active. Previous studies have shown that polyphenols and anthocyanins protect various cells under oxidative stress, but the effects of polyphenols and anthocyanins on cell damage following blue light induction are unknown. The present inventors have completed the present invention by confirming that the phenolic compound separated from the blueberry extract can inhibit the death of blue light-induced retinal pigment epithelial cells by inhibiting intracellular accumulation of A2E.
  • the present invention provides a pharmaceutical composition for treating, preventing or ameliorating macular degeneration, which contains a phenolic compound isolated from the blueberry extract and a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention is fractionated using chloroform, ethyl acetate, butanol, and then subjected to reverse phase HPLC to the ethyl acetate fraction separated phenol compounds and pharmaceutically acceptable salts thereof as an active ingredient. It provides a pharmaceutical composition for the treatment, prevention or improvement of macular degeneration comprising.
  • the invention is a phenolic compound isolated from blueberry extract, mycetin-3-O-galactoside and / or quercetin-3-O-arabinofuranoside, and its pharmaceutically It provides a pharmaceutical composition for the treatment, prevention or improvement of macular degeneration comprising an acceptable salt as an active ingredient.
  • the present invention also provides a method for treating, preventing or ameliorating macular degeneration by administering a phenolic compound isolated from the blueberry extract and a pharmaceutically acceptable salt thereof to a mammal including human.
  • the invention is a phenolic compound isolated from blueberry extract, mycetin-3-O-galactoside and / or quercetin-3-O-arabinofuranoside, and its pharmaceutically Provided are methods of treating, preventing or ameliorating macular degeneration in which an acceptable salt is administered to a mammal, including a human.
  • the present invention also provides the use of a phenolic compound and its pharmaceutically acceptable salts isolated from blueberry extract for the preparation of a pharmaceutical composition for treating, preventing or improving macular degeneration.
  • the present invention provides mycetin-3-O-galactoside and / or quercetin-3-O-arabinofurano isolated from blueberry extract for the preparation of a pharmaceutical composition for treating, preventing or improving macular degeneration. Seed, and pharmaceutically acceptable salts thereof.
  • the present invention also provides a dietary supplement for preventing or improving macular degeneration, which contains a phenolic compound isolated from the blueberry extract and a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a macula, wherein the phenolic compound isolated from the blueberry extract is mycetin-3-O-galactoside and / or quercetin-3-O-arabinofuranoside, and a pharmaceutically acceptable salt thereof.
  • the phenolic compound isolated from the blueberry extract is mycetin-3-O-galactoside and / or quercetin-3-O-arabinofuranoside, and a pharmaceutically acceptable salt thereof.
  • the phenolic compound isolated from the blueberry extract is obtained by fractionating the blueberry extract using chloroform, ethyl acetate, butanol and the like, and then separating and purifying the ethyl acetate fraction using reverse phase HPLC.
  • the phenolic compounds thus obtained include mycetin, mycetin-3-O-galactosid, quercetin, quercetin-3-O-galactosid, quercetin-3-O-arabinofuranoside, and the like. The structure is shown below.
  • blueberry extract is fractionated using a solvent such as chloroform, ethyl acetate, butanol, and the like.
  • the blueberry extract is dissolved in distilled water and continuously fractionated using chloroform, ethyl acetate and butanol, and the ethyl acetate fraction in the solvent fraction may be separated and purified by reverse phase HPLC to separate phenolic compounds.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the phenolic compound isolated from the above-mentioned blueberry extract.
  • a pharmaceutically acceptable carrier are those commonly used in the art, such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally.
  • the dosage form include eye drops, eye ointments, injections, tablets, capsules, granules, powders, and the like, and eye drops or eye ointments are particularly preferable. These can be formulated using techniques that are widely used.
  • eye drops include isotonic agents such as sodium chloride and concentrated glycerin, buffering agents such as sodium phosphate and sodium acetate, surfactants such as polyoxyethylene sorbitan monooleate, polyoxyl stearic acid 40 and polyoxyethylene hydrogenated castor oil, and citric acid Stabilizers, such as sodium and sodium edetate, and preservatives, such as benzalkonium chloride and paraben, etc. can be used as needed.
  • pH should just be in the range permissible for ophthalmic preparations, the range of 4-8 is preferable.
  • the composition of the invention may be provided in the form of a food composition, in particular a functional food composition, ie as a nutraceutical.
  • the functional food composition of the present invention includes ingredients that are commonly added during food production and include proteins, carbohydrates, fats, nutrients and seasonings.
  • Natural carbohydrates include monosaccharides including glucose, fructose and the like; Disaccharides including maltose, sucrose and the like; oligosaccharide; Polysaccharides including dextrin, cyclodextrin and the like; And sugar alcohols including xylitol, sorbitol, erythritol, and the like.
  • natural flavoring agents including tautin, stevia extract and the like, and synthetic flavoring agents including saccharin, aspartame and the like can be used.
  • Phenol compounds isolated from the blueberry extract of the present invention inhibits the intracellular accumulation of A2E, inhibits the death of blue light-induced retinal pigment epithelial cells, and exhibits the effect of treating, preventing or improving macular degeneration.
  • Figure 2 is a schematic diagram showing the process of separating the phenolic compounds from the blueberry extract.
  • FIG. 6 shows the results of confirming that the compound of EA-5 in the phenolic compound is quercetin-3-O-arabinofuranoside.
  • Dried blueberries (100 g of blueberry) were ground with a grinder and extracted twice with hot water (90 ° C., 2000 mL of water) for 16 hours to obtain 10% of blueberry extracts.
  • the obtained extract was lyophilized and stored at -80 ° C until use.
  • Example 2 25 g of the blueberry extract (freeze dried) obtained in Example 1 was dissolved in distilled water as shown in FIG. 2 and fractionated using chloroform, ethyl acetate, and n-butanol continuously. Specifically, the phenolic compounds of the ethyl acetate fraction were separated by the following method.
  • the blueberry extract lyophilized powder was dissolved in distilled water. Separately, two C18 Sep-Pak cartridges were connected, preconditioned with 10 ml ethyl acetate, anhydrous methanol, and 0.01 N aqueous HCl was flowed into the cartridge.
  • Blueberry extract dissolved in distilled water was loaded into the cartridge and carbohydrates / acids and other water-soluble compounds were removed with 6 ml of 0.01 N aqueous HCl.
  • the layer removed was the carbohydrate / acid fraction.
  • Nitrogen gas was passed through a connected C18 Sep-Pak cartridge for 10 minutes to dry the cartridge.
  • Phenolic compounds were collected in a test tube by pouring 20 ml of ethyl acetate into the dried cartridge.
  • the pigment fraction was collected in another test tube using 10 ml of anhydrous methanol containing 0.1% (v / v) HCl.
  • the solvent in the fractions was removed at 40 ° C. using a concentrator.
  • the pigment fraction and the carbohydrate / acid fraction were dissolved in distilled water, and the polyphenol fraction was dissolved in 50% aqueous ethanol and stored at -70 ° C Deer Freezer for use in the experiment.
  • VU-EA-H1 (16.6 mg), VU-EA-H3 (19.8 mg), VU-EA-H5 (6.5 mg) and VU-EA-6 (extracted with HPLC using methanol: water 35:65). 23.5 mg) were isolated and the compounds were mycetin-3-O-galactoside (VU-EA-H1) and quercetin-3-O-galactoside (quercetin-3- O-galactoside: VU-EA-H3), quercetin-3-O-arabinofuranoside (quercetin-3-O-arabinofuranoside: VU-EA-H5) and myricetin (EA-6) (See FIGS. 4-7).
  • Phenolic compounds isolated from the blueberry extract of the present invention can inhibit the accumulation of A2E by inhibiting intracellular accumulation of blue light-induced retinal pigment epithelial cells. Therefore, the phenolic compounds of the present invention can be usefully used for the treatment, prevention or improvement of macular degeneration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour traiter, prévenir ou soulager la dégénérescence maculaire contenant, en tant que substance active, un composé phénolique qui est séparé à partir d'un extrait de Vaccinium uliginosum et un sel pharmaceutiquement acceptable de celui-ci. Le composé phénolique de la présente invention protège la cellule ARPE-19 contre la lumière bleue, de manière à traiter, prévenir ou soulager la dégénérescence maculaire.
PCT/KR2014/000606 2013-01-23 2014-01-22 Composition pour le traitement, la prévention ou le soulagement de la dégénérescence maculaire, contenant un composé phénolique séparé de vaccinium uliginosum extrait en tant que substance active Ceased WO2014116013A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0007402 2013-01-23
KR20130007402A KR101484386B1 (ko) 2013-01-23 2013-01-23 들쭉 추출물로부터 분리된 페놀류 화합물을 유효성분으로 함유하는 황반 변성증의 치료, 예방 또는 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2014116013A1 true WO2014116013A1 (fr) 2014-07-31

Family

ID=51227761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/000606 Ceased WO2014116013A1 (fr) 2013-01-23 2014-01-22 Composition pour le traitement, la prévention ou le soulagement de la dégénérescence maculaire, contenant un composé phénolique séparé de vaccinium uliginosum extrait en tant que substance active

Country Status (2)

Country Link
KR (1) KR101484386B1 (fr)
WO (1) WO2014116013A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111429A1 (fr) * 2015-12-21 2017-06-29 동아제약 주식회사 Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
CN110818553A (zh) * 2019-10-17 2020-02-21 青海师范大学 一种小叶金钱草抗炎化合物及其制备方法
JP2021530460A (ja) * 2018-07-09 2021-11-11 レモネックス インコーポレイテッドLemonex Inc. 黄斑変性の予防または治療用の薬学的組成物および健康機能食品

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102286776B1 (ko) * 2019-11-27 2021-08-06 충남대학교산학협력단 퀘르세틴 3-O-a-L-아라비노퓨라노시드 또는 2―옥소포몰산을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
JP7392219B2 (ja) * 2020-01-20 2023-12-06 株式会社萌芽プランツ フラボノイド組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175720A1 (en) * 2002-04-03 2005-08-11 Mckenzie Maureen A. Vaccinium species compositions with novel beneficial properties
KR20110102246A (ko) * 2010-03-10 2011-09-16 정수영 들쭉 추출물 또는 들쭉 분획물을 유효 성분으로 함유하는 황반 변성증의 치료, 예방 또는 개선용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100616068B1 (ko) * 2004-12-14 2006-08-28 학교법인 한림대학교 들쭉나무 추출물을 포함하는 당뇨병 합병증 저해제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175720A1 (en) * 2002-04-03 2005-08-11 Mckenzie Maureen A. Vaccinium species compositions with novel beneficial properties
KR20110102246A (ko) * 2010-03-10 2011-09-16 정수영 들쭉 추출물 또는 들쭉 분획물을 유효 성분으로 함유하는 황반 변성증의 치료, 예방 또는 개선용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANNEKEN. A. ET AL.: "Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 47, no. 7, 2006, pages 3164 - 3177 *
LAABICH, A. ET AL.: "Protective effects of myricetin and related flavonols against A2E and light mediated- cell death in bovine retinal primary cell culture.", EXPERIMENTAL EYE RESEARCH., vol. 85, no. IS. 1, 2007, pages 151 - 165 *
SU, Z.: "Anthocyanins and Flavonoids of Vaccinium L.", PHARMACEUTICAL CROPS., vol. 3, 2012, pages 7 - 37 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111429A1 (fr) * 2015-12-21 2017-06-29 동아제약 주식회사 Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
KR20170073938A (ko) * 2015-12-21 2017-06-29 동아제약 주식회사 들쭉 추출물을 유효성분으로 포함하는 안구건조증 치료용 조성물
KR102481709B1 (ko) * 2015-12-21 2022-12-27 동아제약 주식회사 들쭉 추출물을 유효성분으로 포함하는 안구건조증 치료용 조성물
JP2021530460A (ja) * 2018-07-09 2021-11-11 レモネックス インコーポレイテッドLemonex Inc. 黄斑変性の予防または治療用の薬学的組成物および健康機能食品
EP3821899A4 (fr) * 2018-07-09 2022-05-04 Lemonex Inc. Composition pharmaceutique et aliment fonctionnel de santé pour prévenir ou traiter la dégénérescence maculaire
JP7152054B2 (ja) 2018-07-09 2022-10-12 レモネックス インコーポレイテッド 黄斑変性の予防または治療用の薬学的組成物および健康機能食品
US11633447B2 (en) 2018-07-09 2023-04-25 Lemonex Inc. Pharmaceutical composition and functional health food for preventing or treating macular degeneration
CN110818553A (zh) * 2019-10-17 2020-02-21 青海师范大学 一种小叶金钱草抗炎化合物及其制备方法

Also Published As

Publication number Publication date
KR20140094847A (ko) 2014-07-31
KR101484386B1 (ko) 2015-01-19

Similar Documents

Publication Publication Date Title
SG174548A1 (en) New salvianolic acid compound l, preparation method and use thereof
KR100626850B1 (ko) 흑미추출물을 이용한 알레르기성 질환 예방 또는 치료용조성물 및 이들의 치료학적 용도
WO2014116013A1 (fr) Composition pour le traitement, la prévention ou le soulagement de la dégénérescence maculaire, contenant un composé phénolique séparé de vaccinium uliginosum extrait en tant que substance active
WO2017213306A1 (fr) Composition pour l'amélioration de la mémoire comprenant un extrait de feuilles de petasites japonicus
WO2024096280A1 (fr) Composition pour la prévention, l'atténuation ou le traitement de la maladie d'alzheimer contenant comme principe actif un extrait de tige de vitis vinifera ou un composé isolé de celui-ci
WO2018026103A1 (fr) Composition pour la régénération cellulaire comprenant un extrait d'axe floral de ginseng
WO2011112002A2 (fr) Composition permettant de traiter, d'empêcher ou de soulager une dégénérescence maculaire contenant un extrait de vaccinium uliginosum ou une fraction de vaccinium uliginosum en tant qu'ingrédient actif
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
KR101811848B1 (ko) 인플루엔자 바이러스 감염의 예방 또는 치료용 커큐미노이드계 화합물/스테비오사이드 함유 복합체
CN106554349B (zh) 野八角新异戊烯基取代c6-c3类化合物及其制备方法、应用和其药物组合物
WO2014073855A1 (fr) Composition comprenant un extrait de substance naturelle ou une fraction associée en tant que principe actif pour la prévention ou le traitement de l'insuffisance rénale aiguë
KR101748301B1 (ko) 질경이 추출물 및 인삼 추출물을 포함하는 퇴행성 뇌질환의 예방, 개선 및 치료용 조성물
WO2017111429A1 (fr) Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
KR101081601B1 (ko) 생강나무로부터 쿼세틴-３-０-알파-람노사이드 및 캠페롤-３-０-알파-람노사이드의 분리 방법 및 그것의 항산화 또는 간 보호 용도
KR101713526B1 (ko) 헛개나무 씨 유래 탁시폴린을 유효성분으로 하는 간독성 질환 치료, 예방 또는 개선용 조성물
WO2021162505A1 (fr) Composé isolé à partir de torilidis fructus et composition pharmaceutique anticancéreuse le contenant en tant que principe actif
KR20210087771A (ko) 어성초 추출물 또는 이로부터 분리한 화합물을 유효성분으로 하는 치매의 예방 또는 치료용 조성물
EP2572713B1 (fr) Extraits et flavonoïdes isolés provenant d'Euphorbia cuneata utiles en tant qu'agents anti-ulcère
WO2022173247A2 (fr) Composition contenant un extrait de chlorella sp. et une fraction phéophytinisée de celui-ci ou composé à base de porphyrine ou de caroténone obtenu à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19
KR20090117452A (ko) 미나리로부터 분리된 신규 화합물 및 그의 용도
WO2025211618A1 (fr) Composition pour améliorer l'obésité ou le métabolisme lipidique comprenant un extrait de rostellularia procumbens
KR20190093849A (ko) 김네마 실베스트레 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
KR20230122507A (ko) 황기 추출물을 유효성분으로 포함하는 난독성 예방 또는 치료용 약학 조성물
WO2017052033A1 (fr) Composition pour le traitement de la dégénérescence maculaire contenant un extrait de myrtille comme principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14743197

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14743197

Country of ref document: EP

Kind code of ref document: A1